The National Heart, Lung, and Blood Institute (NHLBI) awarded a $126,306 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to the University of Washington on December 20, 2024, with a final completion date of November 30, 2026. The grant supports research to establish a high-throughput system for evaluating the functional effects of MYH7 genetic variants associated with hypertrophic cardiomyopathy (HCM) using human induced pluripotent stem cell-derived cardiomyocytes. Additionally, the research aims to identify genetic modifiers that contribute to the variable expressivity of HCM symptoms. The findings from this project are expected to provide clinically actionable information to better classify MYH7 variants and understand factors governing HCM disease severity, improving patient management and care.
Generated 1/28/25, 7:26 AM